| Identification | Back Directory | [Name]
2,6-Diazaspiro[3.3]heptane-2-carboxylic acid, 6-(2,2-difluoroethyl)-, (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester | [CAS]
2081078-92-2 | [Synonyms]
Relzomostat
2,6-Diazaspiro[3.3]heptane-2-carboxylic acid, 6-(2,2-difluoroethyl)-, (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester | [Molecular Formula]
C24H36F2N2O5 | [MOL File]
2081078-92-2.mol | [Molecular Weight]
470.55 |
| Hazard Information | Back Directory | [Uses]
Relzomostat is a methionine aminopeptidase 2 (MetAP2) inhibitor.Relzomostat may be useful for the research of obesity, type 2 diabetes, and other obesity-associated conditions[1]. | [References]
[1] Zahler, Robert; Vath, James E. Preparation of fumagillol spirocyclic and fused bicyclic compounds and their use as MetAP2 inhibitors. WO2017027687A1 |
|
|